Ethanol in tears can cause development of ocular diseases

Article

Orally administered ethanol is secreted into tears and can cause the development of ocular surface diseases.

Orally administered ethanol is secreted into tears and can cause the development of ocular surface diseases, claims a study in the journal Ophthalmology.

The case control study, led by Dr Joo Hyun Kim, Department of Ophthalmology, Hallym University College of Medicine, Seoul, Korea, included 20 healthy male subjects with no prior ocular surface diseases. Ten participants received ethanol orally at 8 pm for two hours and ten were placed in the control group.

The main outcome measures were tear osmolarity, ethanol concentration in tears and serum, Schirmer's test results, tear film break-up time (TBUT), corneal punctuate erosion and corneal sensitivity. Tear film and ocular surface were measured at 6 pm before drinking, at midnight and at 6 am and 8 am the following morning.

Mean tear osmolarity increased in the ethanol group, compared to the control group. The ethanol group demonstrated a significantly shorter TBUT after drinking alcohol.

The fluorescein staining scores were significantly higher in the alcohol group compared to the control group at 6 am and 8 am. However, there were no changes in corneal sensitivity or Schirmer's test results.

Ethanol in tears caused the development hyperosmolarity and reduced TBUT. These changes could worsen signs and symptoms in patients with ocular surface disease.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.